GENEDX INVESTIGATION ALERT: Bragar Eagel & Squire, P.C. Continues Investigating GeneDx Holdings Corp. on Behalf of GeneDx Stockholders and Encourages Investors to Contact the Firm

Core Viewpoint - Bragar Eagel & Squire, P.C. is investigating potential claims against GeneDx Holdings Corp. for possible violations of federal securities laws and unlawful business practices, following allegations of widespread fraud reported by Grizzly Research [1][3]. Summary by Relevant Sections Legal Investigation - The law firm is encouraging GeneDx stockholders who have suffered losses to contact them to discuss their legal rights and options [1][4]. - The investigation is focused on whether GeneDx has engaged in fraudulent activities that could impact its stockholders [1]. Allegations of Fraud - Grizzly Research published a report claiming that GeneDx's growth is largely an illusion, driven by fraudulent schemes aimed at exploiting Medicaid and Medicare systems to inflate revenue [3]. - The report alleges that GeneDx has used a practice known as "code stacking" to bill insurance providers for services that do not meet required criteria [3]. - It was noted that CEO Katherine Stueland and CFO Kevin Feeley have sold their shares immediately upon vesting, suggesting insider knowledge of imminent risks [3]. Stock Market Impact - Following the release of the Grizzly report, GeneDx's stock price fell by $4.84, or 6.72%, closing at $67.18 per share on February 5, 2025 [3].